Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 17, 2026 1 hour, 43 minutes ago
Medical News: A growing number of doctors worldwide are cautiously embracing a new strategy to prevent sexually transmitted infections (STIs), but not without serious reservations. A newly published systematic review is shedding light on what healthcare professionals really think about using doxycycline as a post-exposure preventive treatment, often referred to as doxyPEP.
Doctors cautiously assess a new antibiotic strategy to prevent rising sexually transmitted infections
A Promising Tool Against Rising STI Rates
STIs such as syphilis, chlamydia, and gonorrhea have been rising steadily in recent years, particularly among men who have sex with men (MSM). Traditional prevention strategies like regular testing, condom use, and public health campaigns have not been enough to slow the spread. This has pushed researchers and clinicians to explore alternative methods that could offer better protection.
Doxycycline, a commonly used antibiotic, has emerged as one such option. When taken within 24 to 72 hours after unprotected sexual activity, it has been shown to significantly reduce the risk of certain bacterial STIs. In several studies, reductions were particularly strong for syphilis and chlamydia, while the effect on gonorrhea appeared more moderate due to existing resistance patterns.
Healthcare professionals are clearly paying attention. Across multiple studies involving 1,840 professionals from the United States, the United Kingdom, Australia, and Kenya, many acknowledged the urgent need for new prevention tools and viewed doxyPEP as a potentially valuable addition.
Strong Support - With Important Conditions
While support for doxyPEP is growing, most healthcare providers say its rollout must be carefully controlled. A consistent theme across the studies is the need for clear national guidelines. Many clinicians indicated they would feel more confident prescribing doxyPEP if backed by formal recommendations and structured clinical protocols.
There is also optimism about how doxyPEP could be implemented. Many healthcare professionals believe it could be integrated into existing HIV prevention services, particularly those already offering pre-exposure prophylaxis (PrEP). This would allow clinics to build on current systems rather than creating entirely new ones.
At the same time, some clinicians admitted that their knowledge of doxyPEP is still limited. They highlighted the need for better education and training so they can accurately explain its benefits, risks, and proper use to patients.
Concerns About Antibiotic Resistance
Despite its promise, doxyPEP is not without controversy. The most frequently raised concern is the risk of antimicrobial resistance. Many healthcare professionals fear that widespread use of doxycycline could encourage bacteria to evolve and become harder to treat.
This concern is especially strong for gonorrhea, a pathogen already known for its ability to develop resistance to multiple antibiotics. Some experts believe doxyPEP should be used cautiously or even limited primarily to preventing syphilis, where resistance appears less of an issue.&
lt;br />
In addition to resistance, clinicians also raised concerns about drug interactions, side effects, and the burden of taking additional medication regularly. These factors could affect both patient adherence and overall safety.
Practical Challenges in Real-World Settings
Healthcare providers also pointed to practical barriers that could complicate the rollout of doxyPEP. These include increased workload in sexual health clinics, longer waiting times, and the need for improved systems to manage prescriptions and follow-ups.
Cost is another important consideration. In some countries, access to medication may be limited by affordability, while in others, publicly funded healthcare systems may make implementation easier. These differences could influence how widely doxyPEP is adopted across regions.
Gaps in Research Raise Equity Concerns
Another key issue is the lack of research involving populations beyond MSM. Healthcare professionals expressed concern that groups such as women and transgender individuals are currently underrepresented in studies. This gap means that doctors do not yet have enough evidence to confidently recommend doxyPEP for these populations. As a result, access to this preventive strategy may remain uneven, raising concerns about fairness and inclusivity in healthcare.
A Cautious but Hopeful Outlook
This
Medical News report highlights a clear trend: healthcare professionals are open to innovation but remain cautious about how new tools are introduced. DoxyPEP is widely seen as a promising addition to STI prevention strategies, but not a simple or risk-free solution.
Conclusion
Doxycycline post-exposure prophylaxis has the potential to reshape how sexually transmitted infections are prevented, particularly in high-risk populations. However, its success will depend on careful planning, strong clinical guidelines, and ongoing monitoring of antibiotic resistance. Healthcare professionals are generally willing to adopt this approach, but they stress that more research, better education, and inclusive policies are essential. A balanced and evidence-driven strategy will be crucial to ensure that doxyPEP provides real public health benefits without creating unintended long-term consequences.
The study findings were published in the peer reviewed journal: Venereology.
https://www.mdpi.com/2674-0710/5/1/9
For the latest on STIs, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/stds
Share
Tweet
Share
